Prothena Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Prothena de winst en omzet met respectievelijk 30.8% en 31.6% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 30.7% per jaar.

Belangrijke informatie

30.8%

Groei van de winst

30.7%

Groei van de winst per aandeel

Biotechs winstgroei	27.3%
Inkomstengroei	31.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	03 Nov 2024

Recente toekomstige groei-updates

Recent updates

Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)

Oct 18

Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Oct 02

Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares

Jul 26

Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Jun 19

Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials

Jun 07

New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)

May 14

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 23

Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%

Feb 08

Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?

Dec 20

Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business

Nov 24

Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk

Oct 27

Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Aug 25

What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today

May 10

We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth

Apr 23

Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook

Mar 01

Bearish: Analysts Just Cut Their Prothena Corporation plc (NASDAQ:PRTA) Revenue and EPS estimates

May 08

Winst- en omzetgroeiprognoses

NasdaqGS:PRTA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	225	-128	-89	N/A	5
12/31/2025	88	-231	-135	N/A	8
12/31/2024	144	-126	-172	N/A	8
6/30/2024	217	-51	-101	-99	N/A
3/31/2024	89	-172	-162	-159	N/A
12/31/2023	91	-147	-137	-134	N/A
9/30/2023	141	-73	-89	-88	N/A
6/30/2023	58	-141	-130	-129	N/A
3/31/2023	55	-128	-119	-119	N/A
12/31/2022	54	-117	-109	-109	N/A
9/30/2022	5	-156	-127	-126	N/A
6/30/2022	143	-1	16	17	N/A
3/31/2022	202	67	88	89	N/A
12/31/2021	201	67	92	93	N/A
9/30/2021	200	69	96	96	N/A
6/30/2021	61	-70	-36	-36	N/A
3/31/2021	1	-124	-91	-91	N/A
12/31/2020	1	-111	-81	-80	N/A
9/30/2020	1	-102	-76	-76	N/A
6/30/2020	1	-91	-66	-65	N/A
3/31/2020	1	-80	-59	-59	N/A
12/31/2019	1	-78	-54	-53	N/A
9/30/2019	1	-79	-62	-60	N/A
6/30/2019	1	-84	-86	-84	N/A
3/31/2019	1	-128	-16	-14	N/A
12/31/2018	1	-156	-30	-28	N/A
9/30/2018	1	-181	-47	-47	N/A
6/30/2018	1	-209	-32	-31	N/A
3/31/2018	27	-167	N/A	-125	N/A
12/31/2017	28	-153	N/A	-131	N/A
9/30/2017	27	-154	N/A	-125	N/A
6/30/2017	28	-145	N/A	-138	N/A
3/31/2017	1	-168	N/A	-129	N/A
12/31/2016	1	-160	N/A	-116	N/A
9/30/2016	1	-135	N/A	-102	N/A
6/30/2016	1	-115	N/A	-89	N/A
3/31/2016	1	-93	N/A	-73	N/A
12/31/2015	2	-81	N/A	-59	N/A
9/30/2015	3	-70	N/A	-55	N/A
6/30/2015	4	-60	N/A	-51	N/A
3/31/2015	19	-40	N/A	-33	N/A
12/31/2014	51	-7	N/A	-1	N/A
9/30/2014	49	-5	N/A	2	N/A
6/30/2014	48	-2	N/A	4	N/A
3/31/2014	33	-14	N/A	-9	N/A
12/31/2013	1	-41	N/A	-32	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PRTA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PRTA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PRTA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van PRTA ( 31.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van PRTA ( 31.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PRTA naar verwachting over 3 jaar hoog zal zijn

Prothena Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 8.9% to US$61.14

Price target decreased by 10% to US$56.13

Consensus revenue estimates increase by 496%

Prothena Corporation plc Revises Financial Guidance for the Full Year of 2024

Consensus revenue estimates increase by 59%

Consensus revenue estimates increase by 13%

Recent updates

Price target increased by 8.9% to US$61.14

Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)

Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Prothena Corporation plc Announces Appointment of Chad Swanson as Chief Development Officer

Price target decreased by 10% to US$56.13

Consensus revenue estimates increase by 496%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Prothena Corporation plc Revises Financial Guidance for the Full Year of 2024

Prothena Corporation plc to Report Q2, 2024 Results on Aug 08, 2024

Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares

Consensus revenue estimates increase by 59%

Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials

Consensus revenue estimates increase by 13%

New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)

First quarter 2024 earnings released: US$1.35 loss per share (vs US$0.89 loss in 1Q 2023)

Prothena Corporation plc to Report Q1, 2024 Results on May 08, 2024

Prothena Corporation plc, Annual General Meeting, May 14, 2024

Consensus revenue estimates increase by 26%

Prothena Appoints David Ford to Newly Created Chief People Officer

New major risk - Revenue and earnings growth

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Prothena Corporation plc has filed a Follow-on Equity Offering in the amount of $250 million.

Prothena Corporation plc Announces Board Changes

Consensus revenue estimates fall by 78%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Prothena Corporation plc Provides Earnings Guidance for the Year 2024

Prothena Corporation plc to Report Q4, 2023 Results on Feb 15, 2024

Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%

Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?

Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business

Consensus revenue estimates increase by 63%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Prothena Corporation plc to Report Q3, 2023 Results on Nov 02, 2023

Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk

Prothena Reportedly Prepares for Potential Sale

Chief Accounting Officer & Controller notifies of intention to sell stock

Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Chief Accounting Officer & Controller notifies of intention to sell stock

Consensus revenue estimates increase by 238%

Chief Regulatory Officer notifies of intention to sell stock

Prothena Corporation plc to Report Q2, 2023 Results on Aug 03, 2023

Chief Operating Officer notifies of intention to sell stock

Prothena Corporation plc Presents New Research in the Treatment of Alzheimer's Disease At Alzheimer's Association International Conference®? 2023

Prothena C Corporation plc Announces Phase VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV Al Amyloidosis Treated with Birtamimab

Chief Regulatory Officer exercised options and sold US$1.2m worth of stock

CFO & Chief Strategy Officer exercised options and sold US$4.5m worth of stock

Prothena Corporation plc Appoints Billy Dunn to its Board of Directors

Consensus revenue estimates fall by 29%

What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today

Price target increased by 7.6% to US$92.10

Independent Director notifies of intention to sell stock

Prothena Corporation plc Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth

Chief Accounting Officer & Controller notifies of intention to sell stock

Chief Accounting Officer & Controller notifies of intention to sell stock

Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CFO & Chief Strategy Officer notifies of intention to sell stock

Prothena Corporation plc to Report Q4, 2022 Results on Feb 23, 2023

Prothena Corporation plc Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005

CFO & Chief Strategy Officer notifies of intention to sell stock

Independent Chairman notifies of intention to sell stock

We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate

CFO & Chief Strategy Officer notifies of intention to sell stock

Prothena Corporation plc Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

Independent Chairman exercised options and sold US$874k worth of stock